 About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
|
 |
-
Comment in:
[Serotonin syndrome with fatal outcome caused by selective
serotonin reuptake inhibitors]
[Article in
Norwegian]
Apelland T, Gedde-Dahl T, Dietrichson
T.
Medisinsk avdeling Diakonhjemmets sykehus,
Oslo.
The serotonin syndrome is a rare, but potentially fatal
complication to treatment with serotonin reuptake inhibitors. Due to
increasing prescription of these drugs the condition must be expected to
occur more often. Symptoms include changes in mental status (confusion,
agitation and restlessness), neuromuscular symptoms (shivering, ataxia,
myoclonus and hyperreflexia) and autonomic dysfunction (fever,
diaphoresis, hypertension and tachycardia). The syndrome is most often
produced by concurrent use of two or more drugs that enhance serotonin
neurotransmission. Monotherapy may also elicit the syndrome. We report
the development of serotonin syndrome with a fatal outcome in a patient
treated with paroxetin++. Interactions with alimemazin++, melperon++ and
karbamazepin may have contributed to the outcome. The serotonin syndrome
usually resolves within 24 hours when the suspected drugs are
discontinued. However, there may be a dramatic progression of symptoms
requiring intensive supportive care to prevent death.
Publication
Types:
PMID: 10095385 [PubMed - indexed for
MEDLINE]
|